Overall, our data indicates that the analgesic effect of high dose dasatinib treatment does not result from inhibiting Src phosphorylation at the spinal cord level, but rather from a disease modifying effect on the bone and possibly an anti-proliferative effect on the tumour, causing an indirect anti-nociceptive effect. Here, SRC is linked to neoplasm.